Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the company has received an Issue Notification from the U.S. Patent and Trademark Office for a patent application covering the company’s drug candidate CGEN-25009. CGEN-25009 is intended for the treatment of idiopathic pulmonary fibrosis, a devastating disease with no current effective treatment. This novel peptide agonist of the relaxin receptor was the subject of a recent presentation by Dr. Daniel Kass, from the University of Pittsburgh (“Pitt”), at the 2013 American Thoracic Society Conference.
In his presentation, Dr. Kass, Assistant Professor of Medicine at Pitt and Assistant Director for Novel Therapeutics and Translational Research at The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease at the University of Pittsburgh Medical Center, presented experimental data demonstrating that CGEN-25009 protects mice from bleomycin-induced pulmonary fibrosis. In this model, CGEN-25009 treatment reduced lung fibrosis as determined by collagen deposition in both preventive and therapeutic administration regimens.
Read the entire article at:
http://www.benzinga.com/news/13/07/3751856/compugen-announces-us-patent-allowance-for-drug-candidate-recently-presented-at-2#ixzz2dlvECyB8
For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday
